Headlines about Ohr Pharmaceuticals (NASDAQ:OHRP) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ohr Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.0967113085311 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Some hot names on Wall Street: Overstock.com, Inc. (OSTK), Ohr Pharmaceutical, Inc. (OHRP) – Market Movers (financialqz.com)
- Abeona Therapeutics (ABEO) vs. Ohr Pharmaceuticals (OHRP) Head-To-Head Contrast (americanbankingnews.com)
- Trending Stocks to Observe: Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) – Market Breaking Point (press release) (journalfinance.net)
- Investor’s Roundup (Beta Factor Analysis) – Ohr Pharmaceutical, Inc., (NASDAQ: OHRP) – Stock Watch (stocksnewstimes.com)
- Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) – Today’s Hot Stock Under Review – Alpha Beta Stock (alphabetastock.com)
OHRP has been the topic of a number of recent research reports. Zacks Investment Research raised Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Wednesday, October 18th. ValuEngine raised Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright set a $10.00 price target on Ohr Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Finally, Roth Capital started coverage on Ohr Pharmaceuticals in a research note on Monday, November 27th. They set a “buy” rating and a $7.00 price target on the stock.
ILLEGAL ACTIVITY WARNING: “Ohr Pharmaceuticals (OHRP) Receives Daily Media Impact Score of 0.15” was first published by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://weekherald.com/2017/12/10/ohr-pharmaceuticals-ohrp-receives-daily-media-impact-score-of-0-15.html.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.